Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 4-(5-(3-chloro-5-(trifluoromethyl)-phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2- Oxo-2-((2,2,2-trifluoroethyl)amino)ethyl-1-naphthalenecarboxamide
1. 1093861-60-9
2. Afoxolaner [usan]
3. 02l07h6d0u
4. Afoxolaner (usan)
5. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide
6. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1-naphthamide
7. 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide
8. Afoxolaner [usan:inn]
9. Unii-02l07h6d0u
10. Nexgard
11. Afoxolaner [mi]
12. Afoxolaner [inn]
13. C26h17clf9n3o3
14. Schembl119580
15. Afoxolaner [green Book]
16. Chembl2219412
17. Dtxsid50148921
18. Bcp21108
19. Ex-a3267
20. Afoxolaner [ema Epar Veterinary]
21. Hy-16974
22. Nexgard Spectra Conponent Afoxolaner
23. Cs-0013215
24. Afoxolaner Conponent Of Nexgard Spectra
25. J3.498.573a
26. D10361
27. Q21051346
28. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5- (trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-
29. 1-naphthalenecarboxamide, 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-
30. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl(-n- (2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl(naphthalene-1-carboxamide
31. 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)naphthalene-1-carboxamide
32. 4-[(5r)-5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide
| Molecular Weight | 625.9 g/mol |
|---|---|
| Molecular Formula | C26H17ClF9N3O3 |
| XLogP3 | 6.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 6 |
| Exact Mass | 625.0814726 g/mol |
| Monoisotopic Mass | 625.0814726 g/mol |
| Topological Polar Surface Area | 79.8 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 1040 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of flea infestation in dogs (Ctenocephalides felis and C. canis) for at least 5 weeks. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Treatment of tick infestation in dogs (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus). One treatment kills ticks for up to one month.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Treatment of demodicosis (caused by Demodex canis).
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).
QP53BE01
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Rochem, established in 1994, is a global distributor of pharmaceutical, food, nutritional, and animal health ingredients, sourcing high-quality products from China. Headquartered i...
China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished ...
About the Company : Sichuan Qingmu Pharmaceutical is an innovation-driven company specializing in generic APIs, advanced intermediates, and CDMO/CMO services for small-molecule drugs. Approved by US F...
About the Company : Alivira Animal Health Limited has emerged as India's largest and 1st Global integrated animal health company specialising in manufacturing of Active Pharmaceutical Ingredients (API...

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

About the Company : NGL Fine-Chem Ltd is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. We cater to various global companies to custom manufacture high q...

About the Company : Zenfold Sustainable Technologies (ZST) is a specialty and fine chemicals company, established in 2021. Our advanced technological capabilities and state-of-the-art infrastructure a...

About the Company : Zydus is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Afoxolaner API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Afoxolaner manufacturer or Afoxolaner supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Afoxolaner manufacturer or Afoxolaner supplier.
A Afoxolaner manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Afoxolaner, including repackagers and relabelers. The FDA regulates Afoxolaner manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Afoxolaner API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Afoxolaner manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Afoxolaner supplier is an individual or a company that provides Afoxolaner active pharmaceutical ingredient (API) or Afoxolaner finished formulations upon request. The Afoxolaner suppliers may include Afoxolaner API manufacturers, exporters, distributors and traders.
click here to find a list of Afoxolaner suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Afoxolaner as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Afoxolaner API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Afoxolaner as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Afoxolaner and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Afoxolaner NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Afoxolaner suppliers with NDC on PharmaCompass.
Afoxolaner Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Afoxolaner GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Afoxolaner GMP manufacturer or Afoxolaner GMP API supplier for your needs.
A Afoxolaner CoA (Certificate of Analysis) is a formal document that attests to Afoxolaner's compliance with Afoxolaner specifications and serves as a tool for batch-level quality control.
Afoxolaner CoA mostly includes findings from lab analyses of a specific batch. For each Afoxolaner CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Afoxolaner may be tested according to a variety of international standards, such as European Pharmacopoeia (Afoxolaner EP), Afoxolaner JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Afoxolaner USP).